Biohaven Ltd (BHVN) Stock Price and Analyst Predictions

The stock has a 36-month beta value of 4.14. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for BHVN is 82.39M, and at present, short sellers hold a 12.40% of that float. On September 19, 2024, the average trading volume of BHVN was 921.02K shares.

BHVN) stock’s latest price update

Biohaven Ltd (NYSE: BHVN)’s stock price has increased by 1.03 compared to its previous closing price of 39.00. However, the company has seen a 10.30% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-08-08 that Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven’s Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300: The Company reported dose-dependent and rapid IgG reductions in its ongoing Phase 1 trial with its lead investigational degrader BHV-1300 No serious adverse events (SAEs) reported with BHV-1300 to date; most adverse events (AEs) were mild, deemed unrelated to study drug and resolved spontaneously Phase 1 study also completed an assessment of an optimized subcutaneous (SC) formulation of BHV-1300 that demonstrated approximately a 44% higher than expected exposure compared to the dose-equivalent intravenous formulation previously studied; this new human data further confirms feasibility of convenient self-administered SC auto-injector and the SC formulation was not associated with injection site reactions Degrader platform expected to deliver 3 INDs for new MoDE programs before year-end in addition to continued data from SAD/MAD with BHV-1300 Biohaven’s beta-1 adrenergic receptor (β1AR) autoantibody targeting MoDE, BHV-1600, granted INTERACT meeting with FDA in 2H 2024 regarding development program for dilated cardiomyopathy Advancing novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain and neuropsychiatric disease indications: 5 Phase 2/3 trials with BHV-7000 underway in epilepsy and mood disorders Released positive Phase 1 data with TRPM3 antagonist BHV-2100 showing drug concentrations above EC90 target and well-tolerated profile across all doses in SAD/MAD study; advancing Phase 2 study in acute migraine and proof-of-concept (POC) study in pain in 2H 2024 Taldefgrobep alfa, a myostatin-inhibitor, progressing on track with Phase 3 topline data in spinal muscular atrophy (SMA) and Phase 2 trial initiation in obesity expected in 2H 2024 Taldefgrobep alfa has demonstrated direct effects on reducing adipose tissue (including lipid storage and mitochondrial content) independent of increases in muscle mass In a MAD study, conducted in healthy adults, taldefgrobep alfa (45 mg SC QW) produced significant reductions in total body fat while increasing total body lean mass Preclinical data released at the 2024 American Diabetes Association conference demonstrated that taldefgrobep alfa, as a monotherapy or in combination with a GLP-1 agonist, demonstrated significant reductions in fat and total body weight. Taldefgrobep alfa-treated animals showed significant increases in lean muscle, despite co-administration with a GLP-1 receptor agonist Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) selective inhibitor, BHV-8000, completed Phase 1 and confirmed biomarker target engagement with reductions in inflammatory markers and demonstrated central nervous system penetration with confirmed cerebrospinal fluid (CSF) target exposures in healthy subjects Advancing registrational programs for Parkinson’s disease and prevention of Amyloid-Related Imaging Abnormalities (ARIA) following interactions with the FDA Expect interim data analysis from second ongoing Phase 3 OCD trial with troriluzole in 2H 2024; topline data from first Phase 3 OCD trial expected in 1H 2025 SCA interactions with troriluzole filing in Europe ongoing and constructive interactions in the US with the FDA New real-world evidence (RWE) protocol, incorporating feedback from the FDA, assessing 3-years of treatment with troriluzole expected to deliver topline results in 2H 2024 Biohaven antibody drug conjugate (ADC) portfolio positioned to deliver differentiated profiles and address unmet needs in oncology: BHV-1510 currently dosing cancer patients in Phase1/2 study and now advancing towards combination with Libtayo® by 4Q 2024 Portfolio of multiple advanced nonclinical BHVN ADCs demonstrate improved plasma stability and in vitro/in vivo differentiation NEW HAVEN, Conn.

BHVN’s Market Performance

Biohaven Ltd (BHVN) has seen a 10.30% rise in stock performance for the week, with a -0.88% decline in the past month and a 20.23% surge in the past quarter. The volatility ratio for the week is 4.44%, and the volatility levels for the past 30 days are at 4.28% for BHVN. The simple moving average for the last 20 days is 1.44% for BHVN stock, with a simple moving average of -5.87% for the last 200 days.

Analysts’ Opinion of BHVN

Many brokerage firms have already submitted their reports for BHVN stocks, with Jefferies repeating the rating for BHVN by listing it as a “Buy.” The predicted price for BHVN in the upcoming period, according to Jefferies is $57 based on the research report published on September 16, 2024 of the current year 2024.

Bernstein, on the other hand, stated in their research note that they expect to see BHVN reach a price target of $55. The rating they have provided for BHVN stocks is “Outperform” according to the report published on September 04th, 2024.

Morgan Stanley gave a rating of “Overweight” to BHVN, setting the target price at $58 in the report published on July 24th of the current year.

BHVN Trading at 3.38% from the 50-Day Moving Average

After a stumble in the market that brought BHVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.67% of loss for the given period.

Volatility was left at 4.28%, however, over the last 30 days, the volatility rate increased by 4.44%, as shares sank -3.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.68% upper at present.

During the last 5 trading sessions, BHVN rose by +10.30%, which changed the moving average for the period of 200-days by +18.25% in comparison to the 20-day moving average, which settled at $38.76. In addition, Biohaven Ltd saw -7.94% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BHVN starting from CHILDS JOHN W, who purchase 28,400 shares at the price of $35.67 back on Jul 18 ’24. After this action, CHILDS JOHN W now owns 2,339,741 shares of Biohaven Ltd, valued at $1,012,983 using the latest closing price.

Car Bruce, the Chief Scientific Officer of Biohaven Ltd, purchase 30,000 shares at $33.58 during a trade that took place back on Jun 17 ’24, which means that Car Bruce is holding 30,000 shares at $1,007,490 based on the most recent closing price.

Stock Fundamentals for BHVN

The total capital return value is set at -1.83. Equity return is now at value -193.67, with -137.07 for asset returns.

Based on Biohaven Ltd (BHVN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -16.14.

Currently, EBITDA for the company is -432.68 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.27.

Conclusion

To sum up, Biohaven Ltd (BHVN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.